Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Early Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02699723Early Phase 1Withdrawn

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

Role: lead

NCT02654483Phase 2Completed

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Role: lead

NCT02735356Early Phase 1Completed

Topical Itraconazole in Treating Patients With Basal Cell Cancer

Role: lead

All 3 trials loaded